RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY

Autor: Scott C N Oliver, Richard Y. Hwang, Daniella Santos
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Colorado
Time Factors
Visual acuity
genetic structures
Bevacizumab
Fundus Oculi
Visual Acuity
Angiogenesis Inhibitors
Physical examination
03 medical and health sciences
0302 clinical medicine
Recurrence
Chart review
Wet age-related macular degeneration
medicine
Humans
In patient
030212 general & internal medicine
Dosing
Fluorescein Angiography
Retrospective Studies
Aged
80 and over
Dose-Response Relationship
Drug
medicine.diagnostic_test
business.industry
Incidence
General Medicine
Macular degeneration
medicine.disease
eye diseases
Surgery
Ophthalmology
Receptors
Vascular Endothelial Growth Factor
Intravitreal Injections
Wet Macular Degeneration
030221 ophthalmology & optometry
Female
sense organs
medicine.symptom
business
Tomography
Optical Coherence
Follow-Up Studies
medicine.drug
Zdroj: Retina. 40:679-685
ISSN: 0275-004X
DOI: 10.1097/iae.0000000000002446
Popis: Purpose To determine the recurrence rate of exudative age-related macular degeneration (wet AMD) in patients on 12-week dosing interval anti-vascular endothelial growth factor (anti-VEGF) bevacizumab therapy. Methods A retrospective chart review was performed on wet AMD patients treated with anti-VEGF therapy using a "treat-and-extend" methodology at one physician's practice site over 2 years (2012-2014). Charts were evaluated for visual acuity, anti-VEGF agent used, treatment interval, duration of treatment, trials off of anti-VEGF therapy, evidence of exudation, and wet AMD recurrence characteristics. Results Three hundred and twenty-one wet AMD patients were treated. Fifty-seven eyes were without active exudation by clinical examination or optical coherence tomography (OCT) and were maintained on repeating 12-week interval suppressive anti-VEGF therapy. Sixteen percent (8/49) showed exudation recurrence with an average 10% cumulative recurrence rate per year for eyes on bevacizumab. Eight eyes without active exudation were discontinued off of bevacizumab therapy. Sixty-three percent (5/8) demonstrated recurrence on average 4 months after stopping therapy. Conclusion The findings in this study suggest that if a patient can be extended to 12-week interval bevacizumab therapy, there is on average a 10% chance of recurrence with each successive year. If anti-VEGF therapy is discontinued in these patients, there is an increased chance of recurrence by 4 months.
Databáze: OpenAIRE
Externí odkaz: